| Project/Area Number |
14570155
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
KAKUDO Kennichi Wakayama Medical University, Pathology, Professor, 医学部, 教授 (00112037)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UTSUNOMIYA Hirotoshi Wakayama Medical University, Pathology, Assistant Professor, 医学部, 講師 (60264876)
NAKAMURA Yasushi Wakayama Medical University, Pathology, Assistant Professor, 医学部, 講師 (60275352)
NAKAMURA Misa Wakayama Medical University, Pathology, Assistant Professor, 医学部, 助手 (70285386)
MORI Ichiro Wakayama Medical University, Pathology, Associate Professor, 医学部, 助教授 (10157852)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2003: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2002: ¥2,500,000 (Direct Cost: ¥2,500,000)
|
|---|
| Keywords | breast cancer / retinoic acid receptor β2 / point mutation / loss of heterozygosity / chromosome |
|---|
| Research Abstract |
A growing body of evidence supports the hypotheses that retinoic acid receptor β2 (RAR β2) is a tumor suppressor gene. Although the loss of RAR β2 expression has been reported in many malignant tumors, including breast cancer, the molecular mechanism is still poorly understood. We hypothesized that loss of RAR β2 activity could result from multiple factors, including epigenetic modification and loss of heterozygosity (LOH). Using methylation-specific polymerase chain reaction and LOH analysis, we found that biallelic inactivation via epigenetic changes of both maternal and paternal alleles, or epigenetic modification of one allele combined with genetic loss of the remaining allele, could completely suppress RAR β2 expression in breast cancer. Thus, it is possible that substantial numbers of human cancers arise through suppressor gene silencing via epigenetic mechanisms that inactivate both alleles. Because of this, chromatin-remodeling drugs may provide a novel strategy for cancer prevention and treatment.
|
